Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To describe the prevalence of cystic fibrosis-related diabetes (CFRD) before and after lung transplantation (LT); to analyse the survival and renal function after LT according to the CFRD status before LT.

Methods: Sixty cystic fibrosis (CF) patients transplanted at the Lyon University Hospital between 2004 and 2014 were included. Genotype, pancreatic status, age at LT, survival were recorded. Glucose tolerance status, daily insulin dose requirement, glomerular filtration rate (GFR), and daily glucocorticoid (GC) dose were recorded before LT and until December 2016.

Results: The median follow-up was 5.6 (3.8-8.2) years, and nine patients died. Survival was poorest for patients with CFRD before LT compared with those without CFRD (P = 0.03) but was not correlated with the GFR before LT, with sex, age at LT, or CF genotype. The prevalence of CFRD was 68% at 2 years and 54% at 5 years. For persistent insulin-treated CFRD, the insulin requirement decreased (-2.1 IU/d/y; P < 0.01) and was correlated with the daily GC dose (+0.4 IU/d for one additional milligram, P = 0.012). Seven (11%) patients who had insulin-treated CFRD before LT became nondiabetic after LT, with a median time of 2 (1-4) years. After LT, the GFR decreased (-5.3 ml/min/1.73 m /y; P < 0.001) and was not correlated with the CFRD status before LT.

Conclusions: CFRD before LT is associated with poor survival after LT, which should lead to better management of diabetes. Some patients with pre-LT CFRD became nondiabetic after LT. CFRD is not associated with renal insufficiency after LT.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ppul.24307DOI Listing

Publication Analysis

Top Keywords

cystic fibrosis-related
8
fibrosis-related diabetes
8
lung transplantation
8
renal function
8
cfrd
6
diabetes lung
4
transplantation associated
4
associated lower
4
survival
4
lower survival
4

Similar Publications

Relationship between CFTR variants, sweat chloride responses, and lung function improvements.

Lancet Respir Med

September 2025

Department for Paediatric Pneumology, Allergology, and Neonatology and German Center for Lung Research, Biomedical Research in Endstage and Obstructive Lung Disease, Hannover Medical School, 30625 Hannover, Germany. Electronic address:

View Article and Find Full Text PDF

Background And Aim: Lung transplantation (LTx) is increasingly performed worldwide, yet post-transplant survival remains lower than for other solid organs. Diabetes mellitus (DM) is common among LTx recipients and impacts outcomes. This systematic review evaluates the effects of DM on LTx outcomes and the influence of diabetes onset timing on survival.

View Article and Find Full Text PDF

Bone Disease in Cystic Fibrosis: Insights into Etiopathogenesis and Advances in Treatment Management.

J Clin Med

August 2025

Pediatric Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Piazza G. Cesare 11, 70124 Bari, Italy.

Cystic fibrosis (CF) is a multisystemic genetic disorder caused by dysfunctional CF transmembrane conductance regulator (CFTR) protein, leading to impaired chloride and bicarbonate transport. Advances in care have increased patient lifetime, revealing chronic complications such as CF-related bone disease (CFBD), characterized by low bone mineral density and increased fracture risk. CFBD results from a complex interplay of factors including chronic inflammation, nutritional deficiencies, hormonal imbalances, and impaired glucose metabolism.

View Article and Find Full Text PDF

Cystic Fibrosis (CF) is a genetic disease that primarily affects the pancreas and lungs. CF dyslipidaemia is characterized by decreased circulating lipids and increased ectopic lipid deposition in liver, pancreas, and lungs. Pancreatic exocrine insufficiency precedes the onset of CF related diabetes (CFRD).

View Article and Find Full Text PDF

Background: Cystic fibrosis-related diabetes (CFRD) can be associated with decline in pulmonary function and nutritional status. Earlier diagnosis of CFRD than offered by annual recommended oral glucose tolerance test (OGTT) and earlier initiation of insulin may help prevent clinical decline. This retrospective study investigates the utility of continuous glucose monitoring (CGM) for detection of hyperglycemia in patients with cystic fibrosis (CF).

View Article and Find Full Text PDF